Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 4OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Thoracic 3Tumor-Agnostic 2Breast 1

Conditions

Prostatic Neoplasms 4Neoplasms 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × satraplatin × Genitourinary × Clear all
NCT00450970 2012-08-17

SPERA

Agennix

Phase 3 Terminated
344 enrolled
Genitourinary

Prostatic Neoplasms

NCT00069745 2012-08-07

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

Agennix

Phase 3 Completed
Genitourinary

Prostatic Neoplasms

NCT00313456 2012-05-10

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

Agennix

Phase 1 Terminated
25 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00480623 2012-03-23

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence

Agennix

Phase 1 Terminated
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡